Cutia Therapeutics (HK:2487) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cutia Therapeutics has announced a voluntary update on its CFO and Executive Director, Mr. Huang Yuqing’s, recent purchase of an additional 35,000 company shares, with a total of 85,000 shares acquired in early October 2024 for roughly HK$1.17 million. This investment signifies Mr. Huang’s strong belief in the company’s future and he may consider increasing his stake further. The company assures that it retains sufficient public float in compliance with Hong Kong Exchange rules.
For further insights into HK:2487 stock, check out TipRanks’ Stock Analysis page.